ChincholkarA, KhobragadeD, PathakS. US FDA regulatory framework for generic peptides referring to rDNA origin reference products. J Pharm Res Int. 2022;34(41A):44–49.
2.
MacleodJJ. Insulin and the steps taken to secure an effective preparation. Can Med Assoc J. 1922;12:899–900.
3.
GoeddelDV, KleidDG, BolivarF, . Expression in Escherichia coli of chemically synthesised genes for human insulin. Proc Natl Acad Sci USA. 1979;76:106–110.
4.
OwensDR, LandgrafW, SchmidtA, BretzelRG, KuhlmannMK. The emergence of biosimilar insulin preparations: a cause for concern?Diabetes Technol Ther. 2012;14:989–996.
5.
XiaoW, WangJ, LiuY, . Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther. 2025;10:74.
6.
KleinK, HeisterbergJ, StolkP. Synthetic polypeptides using a biologic as a reference medicinal product: the European landscape of regulatory approvals. Front Med (Lausanne). 2024;11:1335928.
7.
US Food and Drug Administration. Regulatory information. Accessed April10, 2026. https://www.fda.gov/media/107622/download
8.
PraveenRB, RaghavanV, IswareyaaRA. A comprehensive review of regulatory requirements and approval pathways for peptide therapeutics in the USA and India. Int J Pharm Sci. 2026;4. doi: 10.5281/zenodo.18672906
9.
LeviJ, CrossS, RameshN, VenterF, HillA. How low could semaglutide prices fall? An analysis of production cost and implications for global access ahead of patent expiry. medRxiv. 2026;2026.03.04.26347508. doi: 10.64898/2026.03.04.26347508
